Activating a cell protein to prevent early dialysis fistula failure
Integrin Activation to Prevent Early Arteriovenous Fistula Failure in End-stage Renal Disease Patients
['FUNDING_R01'] · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · NIH-11262322
This research tests a drug-like activator of the Mac-1 protein to reduce inflammation and help new dialysis fistulas work better for people with end-stage kidney disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (CORAL GABLES, UNITED STATES) |
| Trial ID | NIH-11262322 on ClinicalTrials.gov |
What this research studies
If you are getting or have just received a new arteriovenous (A-V) fistula for hemodialysis, this work aims to reduce the inflammation that causes early narrowing and scarring. Researchers are testing a newly discovered activator of the Mac-1 integrin to control macrophage and myeloid cell activity after fistula surgery. The team will use genetic and drug-based approaches in laboratory and animal models to see whether Mac-1 activation prevents intimal hyperplasia and fibrosis that block fistula blood flow. Successful preclinical results would support future testing of this approach in people.
Who could benefit from this research
Good fit: Ideal candidates are adults with end-stage renal disease who are planning to receive or have recently received a new autogenous A-V fistula for hemodialysis.
Not a fit: Patients who are not on hemodialysis, who already have a mature functioning fistula, or whose fistula problems are due to causes other than post-operative inflammation may not benefit from this work.
Why it matters
Potential benefit: If successful, this approach could lower early fistula failure rates and reduce the need for additional procedures to make dialysis access usable.
How similar studies have performed: Anti-inflammatory strategies for fistula failure have shown mixed clinical results, and Mac-1 activation is a novel, mostly preclinical approach with encouraging early signs but not yet tested in humans.
Where this research is happening
CORAL GABLES, UNITED STATES
- UNIVERSITY OF MIAMI SCHOOL OF MEDICINE — CORAL GABLES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VAZQUEZ PADRON, ROBERTO IRENARDO — UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- Study coordinator: VAZQUEZ PADRON, ROBERTO IRENARDO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.